TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies.
about
Clinical perspectives of TRAIL: insights into central nervous system disordersCell-to-cell variability in cell death: can systems biology help us make sense of it all?Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAPBH3-mimetics- and cisplatin-induced cell death proceeds through different pathways depending on the availability of death-related cellular componentsModulating cell-to-cell variability and sensitivity to death ligands by co-drugging.Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells.Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.Multi-layered nanoparticles for combination gene and drug delivery to tumors.Intra- and interdimeric caspase-8 self-cleavage controls strength and timing of CD95-induced apoptosis.Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine.Mitochondrial division inhibitor 1 (mdivi-1) enhances death receptor-mediated apoptosis in human ovarian cancer cells.TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells.Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis.TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.A promising "TRAIL" of tanshinones for cancer therapy.Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation.Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.Clinical targeting of the TNF and TNFR superfamiliesNiacin alleviates TRAIL-mediated colon cancer cell death via autophagy flux activation.Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapesThe pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes.Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells.TRAIL on trial: preclinical advances in cancer therapyActivation of autophagic flux by epigallocatechin gallate mitigates TRAIL-induced tumor cell apoptosis via down-regulation of death receptors.Decursin enhances TRAIL-induced apoptosis through oxidative stress mediated- endoplasmic reticulum stress signalling in non-small cell lung cancersGold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cellsNon-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches?Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities.Double gene siRNA knockdown of mutant p53 and TNF induces apoptosis in triple-negative breast cancer cells.Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer.Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancerElevated Pressure Enhanced Trail-Induced Apoptosis in Hepatocellular Carcinoma Cells Via Erk1/2-Inactivation.Key regulators of apoptosis execution as biomarker candidates in melanoma
P2860
Q26766570-7DE668F5-DD64-4A95-B563-22C8622465F4Q27013063-5B3A79E8-F9A0-4650-BB5E-601F08E27CA5Q28283505-992DB90E-E29E-47C1-AA83-30C4263B9BBAQ28486502-F747A82D-F68D-4F9D-8A64-CD6B307EA26FQ30544925-5778824F-876F-4E66-A2B7-5D399EF6A450Q30549646-81BAFB02-28B6-443B-822A-0D74897B25D1Q33576187-B0118260-0BC5-4986-A664-B3FAF5CA6C64Q33591623-07FCFFAC-5E9A-4BE6-AE73-9DBE61CBA3BEQ34028460-380A897A-8915-43FD-ADA3-6322A5A86E97Q34135640-5F577745-B69B-4E11-B637-147DA5CA13D2Q34400187-0B968368-5CFA-44B0-B5FE-821A2D31DF2AQ34402129-F76B8B94-D53C-4BC5-8D73-F2B42EDFA20AQ34980905-0B7F4396-92BA-4216-8A55-D4B8BE7CA8BBQ35089228-B59C56C5-B031-4692-A320-415DCE1CD344Q35344969-E70C2A59-B384-4E53-8F27-250E5FF38600Q35681794-116ABE07-4AAA-4BB4-AFCF-18848C748C84Q35922585-33A7A14E-FAFE-4DE0-AF4D-D94CFB9E10FFQ36103378-5F084472-A9D0-41CE-8A81-C156CD1E5756Q36216032-438389D3-2400-49E8-AD18-B35DB5E9F131Q36332681-3557813E-DD5C-4582-87BB-7C2A9F2E9EEAQ36347307-B81A7C47-4018-4B32-AE29-557576BAD946Q36395984-0C62BD93-4B58-48C0-96AB-D9E4D5D33A06Q36762882-E7037855-B17A-4F86-9897-5F494D873B15Q36782440-7EFEB9F8-B34A-4FFE-8757-DAA0FEC43C8FQ36952911-D2978BB2-9844-49B3-9EE4-5231A1C2E24EQ36992184-9580803B-59D1-495C-9235-B788AB43AB4BQ37003894-F5A27C2A-88B0-40BA-A6D7-6113D1B43E15Q37029804-0E3C3007-421A-4C7C-9C9D-623818F2E4D7Q37433463-63FE026A-F2D9-4245-8A27-43E0B17D7820Q37662292-AA094D88-3E96-45E7-960B-BF4C09E1DB73Q37686138-1F172948-DDCF-4246-987E-4ECBAC8D3540Q37739975-E21FB1C5-785A-4E99-A9B4-72512FA7498BQ38098380-29DA41E5-95B5-44A1-BA5B-A880427DEFABQ38183302-2FAC8B7C-6374-40B8-B4AD-9A69A0BA6F18Q38575137-05FB8F0C-F446-4DAA-90B1-DC0C6A02DF4FQ38726515-FEE0FC27-C652-4DD8-906F-88E1652BCE6CQ38797635-467C4F20-69C8-4239-BA00-41F3458EE88AQ38839654-057B651F-0168-4961-B53C-2AD1B1CD1D31Q38858746-E6C78F85-166E-4493-88A7-65D28702CCB1Q38866722-60842BE8-826D-4C5D-A339-0C7D8106BFDA
P2860
TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies.
@en
TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies.
@nl
type
label
TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies.
@en
TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies.
@nl
prefLabel
TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies.
@en
TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies.
@nl
P1476
TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies.
@en
P2093
Christian T Hellwig
P356
10.1158/1535-7163.MCT-11-0434
P50
P577
2012-01-01T00:00:00Z